NASDAQ:NBTX Nanobiotix (NBTX) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free NBTX Stock Alerts $6.28 -0.67 (-9.64%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$6.21▼$6.5150-Day Range$6.25▼$8.1352-Week Range$1.75▼$11.00Volume24,289 shsAverage Volume8,065 shsMarket Capitalization$295.98 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Nanobiotix alerts: Email Address Nanobiotix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.2% Upside$11.00 Price TargetShort InterestHealthy0.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.15) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.86 out of 5 starsMedical Sector635th out of 947 stocksPharmaceutical Preparations Industry289th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingNanobiotix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Nanobiotix has a forecasted upside of 75.2% from its current price of $6.28.Amount of Analyst CoverageNanobiotix has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.09% of the outstanding shares of Nanobiotix have been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanobiotix has recently increased by 0.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNanobiotix does not currently pay a dividend.Dividend GrowthNanobiotix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NBTX. Previous Next 2.7 News and Social Media Coverage News SentimentNanobiotix has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.MarketBeat Follows1 people have added Nanobiotix to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nanobiotix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.45% of the stock of Nanobiotix is held by insiders.Percentage Held by InstitutionsOnly 9.93% of the stock of Nanobiotix is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nanobiotix are expected to grow in the coming year, from ($1.15) to ($0.86) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Nanobiotix Stock (NASDAQ:NBTX)Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Read More NBTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBTX Stock News HeadlinesMarch 12, 2024 | americanbankingnews.comNanobiotix (NASDAQ:NBTX) Trading Down 4.1%March 6, 2024 | globenewswire.comNanobiotix to Present at Upcoming Investor Conferences in MarchMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:January 31, 2024 | finance.yahoo.comNanobiotix to Present at the Guggenheim 6th Annual Biotechnology ConferenceJanuary 30, 2024 | finanznachrichten.deNanobiotix S.A.: Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyJanuary 29, 2024 | finance.yahoo.comNanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyJanuary 18, 2024 | seekingalpha.comNBTX Nanobiotix S.A.December 8, 2023 | realmoney.thestreet.comNanobiotix initiated with an Outperform at LeerinkMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.December 4, 2023 | finance.yahoo.comNanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.November 15, 2023 | finanznachrichten.deNanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2023 Operational and Financial UpdateNovember 13, 2023 | finance.yahoo.comNANOBIOTIX Provides Third Quarter 2023 Operational and Financial UpdateNovember 9, 2023 | finance.yahoo.comNANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023November 9, 2023 | finanznachrichten.deNanobiotix S.A.: Voting Rights and Shares Capital of the CompanyNovember 7, 2023 | finance.yahoo.comNANOBIOTIX Announces Closing of Global OfferingNovember 6, 2023 | finance.yahoo.comNANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6MNovember 2, 2023 | msn.comWhy Nanobiotix (NBTX) Stock Is Plunging ThursdayNovember 2, 2023 | finance.yahoo.comNANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55MNovember 2, 2023 | morningstar.comNanobiotix SA ADR NBTXNovember 1, 2023 | finance.yahoo.comNANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash CovenantOctober 23, 2023 | finance.yahoo.comNANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023October 5, 2023 | msn.comNanobiotix falls after Phase 1 data for lead asset in head and neck cancerOctober 5, 2023 | markets.businessinsider.comUBS Reaffirms Their Buy Rating on Nanobiotix (NBTX)October 4, 2023 | finance.yahoo.comNanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 MonthsSeptember 29, 2023 | finance.yahoo.comNANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation OncologySeptember 28, 2023 | finance.yahoo.comNANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic CancerSeptember 27, 2023 | finanznachrichten.deNanobiotix S.A.: NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023See More Headlines Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Next Earnings (Estimated)4/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NBTX CUSIPN/A CIK1760854 Webwww.nanobiotix.com Phone33-1-40-26-04-70FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+75.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick RatioN/A Sales & Book Value Annual Sales$5.12 million Price / Sales57.81 Cash FlowN/A Price / Cash FlowN/A Book Value($0.82) per share Price / Book-7.66Miscellaneous Outstanding Shares47,130,000Free Float45,507,000Market Cap$295.98 million OptionableNot Optionable Beta0.20 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Laurent Levy Ph.D. (Age 51)Co-Founder, President of the Executive Board & CEO Comp: $688.6kMr. Bart Van Rhijn (Age 51)CFO & Member of Executive Board Comp: $610.86kMs. Anne-Juliette Hermant M.A. (Age 50)Chief People Officer & Member of Executive Board Comp: $335.82kMr. Earl J. Bergey Ph.d. (Age 69)Co-Founder Mr. Alain DostieChief Operating OfficerMr. Craig West CFASenior Vice President of Investor RelationsMr. Brandon OwensVP of Strategic Marketing & Corporate CommunicationMr. Patrick Tricoli M.B.A.Pharm.D., Global Head of Business DevelopmentMs. Margaret GalluzziVP & Global Head of Clinical OperationsMr. Ventzislav Vassilev M.D.VP & Global Head of Safety VigilanceMore ExecutivesKey CompetitorsGossamer BioNASDAQ:GOSSAtai Life SciencesNASDAQ:ATAIAdlai NortyeNASDAQ:ANLErascaNASDAQ:ERASEnanta PharmaceuticalsNASDAQ:ENTAView All CompetitorsInstitutional OwnershipBaillie Gifford & Co.Bought 932,835 shares on 1/26/2024Ownership: 6.087%View All Institutional Transactions NBTX Stock Analysis - Frequently Asked Questions Should I buy or sell Nanobiotix stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NBTX shares. View NBTX analyst ratings or view top-rated stocks. What is Nanobiotix's stock price target for 2024? 2 Wall Street analysts have issued 1 year target prices for Nanobiotix's stock. Their NBTX share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 75.2% from the stock's current price. View analysts price targets for NBTX or view top-rated stocks among Wall Street analysts. How have NBTX shares performed in 2024? Nanobiotix's stock was trading at $7.28 at the beginning of the year. Since then, NBTX stock has decreased by 13.7% and is now trading at $6.28. View the best growth stocks for 2024 here. When is Nanobiotix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024. View our NBTX earnings forecast. When did Nanobiotix IPO? (NBTX) raised $95 million in an IPO on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO. Who are Nanobiotix's major shareholders? Nanobiotix's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (6.09%). How do I buy shares of Nanobiotix? Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBTX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.